Skip to main content

Regulatory and Washington

  • Colonial Life: Three healthcare trends that can impact retail pharmacy in 2012

    COLUMBIA, S.C. — Colonial Life and Accident Insurance last week released its top five trends and predictions for health care in 2012 — three of which may have some direct impact on retail pharmacy.

  • CRN to host free webinar on supplement regs for Pharmacist Society

    WASHINGTON — Dietary supplement usage is up among Americans, according to a National Center for Health Statistics report released earlier this year — half of all U.S. adults supplement their diets, most likely with a multivitamin. And pharmacists are the No. 2 go-to source (behind doctors) for information around those supplements — according to a Council for Responsible Nutrition Survey on Dietary Supplements.

    As a pharmacist, are you prepared to answer their questions?

  • Legislation aimed at closing tax loophole receives NACDS endorsement

    ALEXANDRIA, Va. — Legislation that would level the playing field for brick-and-mortar retailers, including pharmacies, by closing a loophole that puts them at a disadvantage with online retailers has received praise from the National Association of Chain Drug Stores.

    Sen. Mike Enzi, R-Wy., is the sponsor of the Marketplace Fairness Act and serves as the ranking Republican member of the Committee on Health, Education, Labor and Pensions.

  • Appeals court rejects Teva request to stop Watson from selling generic Seasonique

    PARSIPPANY, N.J. — An appeals court has thrown out an attempt by Teva Pharmaceutical Industries to stop Watson Pharmaceuticals from selling a generic contraceptive, Watson said.

    The U.S. Court of Appeals for the Federal Circuit affirmed a lower court's June 16 decision to deny Duramed Pharmaceuticals' request for an injunction that would stop Watson from selling a generic version of Seasonique (levonorgestrel and ethinyl estradiol [0.15 mg/0.03 mg] and ethinyl estradiol [0.01 mg]). Duramed originally was a subsidiary of Barr Pharmaceuticals, which Teva acquired in 2008.

  • Watson launches generic painkiller

    PARSIPPANY, N.J. — Watson Pharmaceuticals has launched its generic version of an opioid drug for treating pain, the company said Thursday.

    Watson announced the Food and Drug Administration approval and launch of morphine sulfate extended-release capsules.

    The drug is a generic version of Actavis' Kadian, which had sales of about $275 million during the 12-month period ended in September, according to IMS Health.

  • CDC: 7-in-10 smokers want to quit; half have tried in past year

    ATLANTA — Most American adults who smoke wish they could quit, and more than half have tried within the past year, according to a report by the Centers for Disease Control and Prevention released Thursday.

  • Watson files for approval of generic dementia treatment

    PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging three of Swiss drug maker Novartis' patents on a drug used to treat dementia, Watson said.

    The company said subsidiary Watson Labs had filed for approval generic rivastigmine transdermal system patches in the 4.6-mg and 9.5-mg strengths, both designed to last for 24 hours, with the Food and Drug Administration. The patches are used to treat mild to moderate dementia associated with Alzheimer's or Parkinson's disease.

  • Surveys: HSA utilization on the rise

    DALLAS — Employers and consumers alike are adopting health savings accounts as a viable way to manage their healthcare costs without compromising care, according to two national surveys released Thursday.

X
This ad will auto-close in 10 seconds